Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05757713 · ClinicalTrials.gov registry record · Phase 4
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
A Phase 4 study of Diabetes Mellitus, Type 1, sponsored by Sanofi.
- Active
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 10
- Study locations
NCT05757713: Active Phase 4 study of Diabetes Mellitus, Type 1, sponsored by Sanofi.
NCT05757713 is a Phase 4 study of Diabetes Mellitus, Type 1 that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 20 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05757713, a Phase 4 study of Diabetes Mellitus, Type 1, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to assess the safety and pharmacokinetics (PK) of teplizumab in participants with Stage 2 type 1 diabetes who are \<8 years of age.
Primary Outcome
Safety and tolerability endpoint
Conditions Studied
Interventions
- BIOLOGICAL teplizumab
Study Locations (10)
California
- UCSF Medical Center Site Number : 107 - San Francisco
Colorado
- Barbara Davis Center for Diabetes Site Number : 102 - Aurora
Connecticut
- Yale University School of Medicine Site Number : 101 - New Haven
Georgia
- Centricity Research Site Number : 104 - Columbus
Indiana
- Indianapolis University Health Riley Hospital for Children Site Number : 110 - Indianapolis
New York
- UBMD Pediactrics Site Number : 105 - Buffalo
Pennsylvania
- Children's Hospital of Philadelphia Site Number : 108 - Philadelphia
South Dakota
- Sanford Diabetes and Thyroid Clinic Site Number : 106 - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-07-25 |
| Est. Completion | 2026-08-27 |
| Phase | Phase 4 |
What the registry record for NCT05757713 still lists
NCT05757713 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 1 intervention - of which teplizumab is the first listed.
NCT05757713 lists 10 locations in 10 states (California, Colorado, Connecticut).
Frequently Asked Questions
What is clinical trial NCT05757713 about?
NCT05757713 is a clinical study titled "Teplizumab in Pediatric Stage 2 Type 1 Diabetes". The purpose of this study is to assess the safety and pharmacokinetics (PK) of teplizumab in participants with Stage 2 type 1 diabetes who are \<8 years of age.
What is the current status of trial NCT05757713?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2023-07-25. Estimated completion is 2026-08-27.
What conditions does trial NCT05757713 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT05757713?
The interventions under investigation include: teplizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05757713?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05757713 being conducted?
This trial has 10 study locations across California, Colorado, Connecticut, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05757713's enrollment target sits among peer trials
20 96th of 118 higher than 16 of 118 other Diabetes Mellitus, Type 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus
ACTIVE NOT RECRUITING · Phase 4
-
Afrezza® Dosing Optimization Study
COMPLETED · Phase 4
-
Sitagliptin Dose Determination Study
COMPLETED · Phase 4
-
Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.
COMPLETED · Phase 4
-
NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
COMPLETED · Phase 4
-
Comparison of Glycemic Control Achieved With 2 Different Needles
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI